AI-generated analysis. Always verify with the original filing.
vTv Therapeutics Inc. reported financial results for the fourth quarter and full year ended December 31, 2025, highlighting a net loss of $7.1 million for the quarter and $27.0 million for the year. The company also announced a $20.0 million payment received in February 2026 from an amended licensing agreement with Newsoara Biopharma Inc. and projected completion of enrollment in its CATT1 Phase 3 trial in the third quarter of 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
Results of Operations and Financial Condition On March 10, 2026, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal y
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release dated March 10 202 6 , announcing financial results for the fiscal yea
| Metric | Value | Basis |
|---|---|---|
| Revenue | $0.00 | |
| Research and Development Expenses | $3.90 | |
| General and Administrative Expenses | $4.00 | |
| Net Loss attributable to vTv Therapeutics Inc. | $7.10 | |
| Net Loss Per Share Basic | $0.58 | |
| Revenue | $0.00 | |
| Research and Development Expenses | $17.90 | |
| General and Administrative Expenses | $14.90 | |
| Net Loss attributable to vTv Therapeutics Inc. | $27.00 | |
| Net Loss Per Share Basic | $3.20 |
Material Agreement